Tobin Schilke - Mar 15, 2023 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role
CFO
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Stock symbol
RVNC
Transactions as of
Mar 15, 2023
Transactions value $
-$114,600
Form type
4
Date filed
3/17/2023, 03:21 PM
Previous filing
Mar 2, 2023
Next filing
Apr 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Tax liability -$115K -3.74K -5.11% $30.65 69.5K Mar 15, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock award (the"RSA") for 7,540 shares. The RSA vests in three equal annual installments from March 15, 2021.